In vitro growth inhibition of ovarian cancer cells by decorin: Synergism of action between decorin and carboplatin

Cancer Research

Volumn 59, Issue 24, 1999, Pages 6192-6196

  Nash, Micheal A ^a   Loercher, Amy E ^a   Freedman, Ralph S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DECORIN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P21;

ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; GENE ACTIVATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; ONCOGENE C MYC; OVARY CANCER; PRIORITY JOURNAL; REGULATORY MECHANISM;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DRUG SYNERGISM; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GROWTH INHIBITORS; HUMANS; OVARIAN NEOPLASMS; PROTEOGLYCANS; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0033572612     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Brucks, J. A. Ovarian cancer. The most lethal gynecologic malignancy. Nurs. Clin. N. Am., 27: 835-845, 1992.
2. Iozzo, R. V. The family of the small leucine-rich proteoglycans: key regulators of matrix assembly and cellular growth. Crit. Rev. Biochem. Biol., 32: 141-174, 1997.
3. Santra, M., Mann, D. M., Mercer, E. W., Skorski, T., Calabretta, B., and Iozzo, R. V. Ectopic expression of decorin protein core causes a generalized growth suppression in neoplastic cells of various histogenetic origin and requires endogenous p21, an inhibitor of cyclin-dependent kinases. J. Clin. Investig., 100: 149-157, 1997.
4. Moscatello, D. K., Santra, M., Mann, D. M., McQuillan, D. J., Wong, A. J., and Iozzo, R. V. Decorin suppresses tumor cell growth by activating the epidermal growth factor receptor. J. Clin. Investig., 101: 406-412, 1998.
5. Hausser, H., Schonherr, E., Muller, M., Liszio, C., Bin, Z., Fisher, L. W., and Kresse, H. Receptor-mediated endocytosis of decorin: involvement of leucine-rich repeat structures. Arch. Biochem. Biophys., 349: 363-370, 1998.
6. Hildebrand, A., Romaris, M., Rasmussen, L. M., Heinegard, D., Twardzik, D. R., Border, W. A., and Ruoslahti, E. Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor β. Biochem. J., 302: 527-534, 1994.
7. Ständer, M., Naumann, U., Dumitrescu, L., Heneka, M., Loschmann, P., Gulbins, E., Dichgans, J., and Weller, M. Decorin gene transfer-mediated suppression of TGF-β; synthesis abrogates experimental malignant glioma growth in vivo. Gene Ther., 5: 1187-1194, 1998.
8. Hirsch, C. S., Ellner, J. J., Blinkhorn, R., and Toossi, Z. In vitro restoration of T cell responses in tuberculosis and augmentation of monocyte effector function against Mycobacterium tuberculosis by natural inhibitors of transforming growth factor β. Proc. Natl. Acad. Sci. USA, 94: 3926-3931, 1997.
9. Merle, B., Malaval, L., Lawler, J., Delmas, P., and Clezardin, P. Decorin inhibits cell attachment to thrombospondin-1 by binding to a KKTR-dependent cell adhesive site present within the N-terminal domain of thrombospondin-1. J. Cell. Biochem., 67: 75-83, 1997.
10. Wang, T. N., Qian, X., Granick, M. S., Solomon, M. P., Rothman, V. L., Berger, D. H., and Tuszynski, G. P. Thrombospondin-1 (TSP-1) promotes the invasive properties of human breast cancer. J. Surg. Res., 63: 39-43, 1996.
11. Murphy-Ullrich, J. E., Schultz-Cherry, S., and Hook, M. Transforming growth factor-β complexes with thrombospondin. Mol. Biol. Cell, 3: 181-188, 1992.
12. Teti, A., De Giorgi, A., Spinella, M. T., Migliaccio, S., Canipari, R., Onetti Muda, A., and Faraggiana, T. Transforming growth factor-β enhances adhesion of melanoma cells to the endothelium in vitro. Int. J. Cancer. 72: 1013-1020, 1997.
13. Teicher, B. A., Ikebe, M., Ara, G., Keyes, S. R., and Herbst, R. S. Transforming growth factor-β1 overcxpression produces drug resistance in vivo: reversal by decorin. In Vivo, 11: 463-472, 1997.
14. Teicher, B. A., Maehara, Y., Kakeji, Y., Ara, G., Keyes, S. R., Wong, J., and Herbst, R. Reversal of in vivo drug resistance by the transforming growth factor-β inhibitor decorin. Int. J. Cancer. 71: 49-58, 1997.
15. Iozzo, R. V., and Cohen, I. Altered proteoglycan gene expression and the tumor stroma. Exper. Suppl. (Basel), 70: 199-214, 1994.
16. Freedman, R. S., Pihl, E., Kusyk, C., Gallager, H. S., and Rutledge, F. Characterization of an ovarian carcinoma cell line. Cancer (Phila.), 42: 2352-2359, 1978.
17. Kloen, P., Jennings, C. L., Gebhardt, M. C., Springfield, D. S., and Mankin, H. J. Expression of transforming growth factor-β (TGF-β) receptors. TGF-β1 and TGF-β2 production and autocrine growth control in osteosarcoma cells. Int. J. Cancer, 58: 440-445, 1994.
18. Yamaguchi, Y., Mann, D. M., and Ruoslahti, E. Negative regulation of transforming growth factor-β by the proteoglycan decorin. Nature (Lond.), 346: 281-284, 1990.
19. Harlow, E., and Lane, D. Antibodies, A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1988.
20. Sambrook, J., Fritsch, E. F., and Maniatis, T. Molecular Cloning, A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
21. Nash, M. A., Lenzi, R., Platsoucas, C. D., and Freedman, R. S. RT-PCR quantitation of cytokine responses in vivo from specimens containing small numbers of cells during bioimmunotherapy. J. Immunol. Methods, 219: 169-179, 1998.
22. Berenbaum, M. C. Criteria for analyzing interactions between biologically active agents. Adv. Cancer Res., 35: 269-335, 1981.
23. Ferrandina, G., Melichar, B., Loercher, A., Verschraegen, C. F., Kudelka, A. P., Edwards, C. L., Scambia, G., Kavanagh, J. J., Abbruzzese, J. L., and Freedman, R. S. Growth inhibitory effects of sodium phenylacetate (NSC 3039) on ovarian carcinoma cells in vitro. Cancer Res., 57: 4309-4315, 1997.
24. Hurteau, J., Rodriguez, G. C. Whitaker, R. S., Shah, S., Mills, G., Bast, R. C., and Berchuck, A. Transforming growth factor-β inhibits proliferation of human ovarian cancer cells obtained from ascites. Cancer (Phila.), 74: 93-99, 1994.
25. Hirte, H., and Clark, D. A. Generation of lymphokine-activated killer cells in human ovarian carcinoma ascitic fluid: identification of transforming growth factor-β as a suppressive factor. Cancer Immunol. Immunother., 32: 296-302, 1991.
26. Zeinoun, Z., Teugels, E., De Bleser, P. J., Neyns, B., Geerts, A., and De Greve, J. Insufficient TGF-β1 production inactivates the autocrine growth suppressive circuit in human ovarian cancer cell lines. Anticancer Res., 19: 413-420, 1999.
27. Nash, M. A., Lenzi, R., Edwards, C. L., Kavanagh, J. J., Kudelka, A. P., Verschraegen, C. F., Platsoucas, C. D., and Freedman, R. S. Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumor specimens, peritoneal exudate cells containing tumor, TIL-derived T-cell lines and established tumor cell lines. Clin. Exp. Immunol., 112: 172-180, 1998.
28. Nash, M. A., Ferrandina, G., Gordinier, M., Loercher, A., and Freedman, R. S. The role of cytokines in both the normal and malignant ovary. Endocrine-Related Cancer, 6: 93-107, 1999.
29. Cutry, A. F., Kinniburgh, A. J., Twardzik, D. R., and Wenner, C. E. Transforming growth factor α (TGF α) induction of C-FOS and C-MYC expression in C3H 10T1/2 cells. Biochem. Biophys. Res. Commun., 152: 216-222, 1988.
30. Border, W. A., Noble, N. A., Yamamoto, T., Harper, J. R., Yamaguchi, Y., Pierschbacher, M. D., and Ruoslahti, E. Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature (Lond.), 360: 361-364, 1992.
31. De Luca, A., Santra, M., Baldi, A., Giordano, A., and Iozzo, R. V. Decorin-induced growth suppression is associated with up-regulation of p21, an inhibitor of cyclin-dependent kinases. J. Biol. Chem., 271: 18961-18965, 1996.
32. Chumakov, A. M., Miller, C. W., Chen, D. L., and Koeffler, H. P. Analysis of p53 transactivation through high-affinity binding sites. Oncogene, 8: 3005-3011, 1993.
33. Berchuck, A., and Carney, M. Human ovarian cancer of the surface epithelium. Biochem. Pharmacol., 54: 541-544, 1997.
34. Ramakrishna, V., Negri, D. R. M., Brusic, V., Fontanelli, R., Canevari, S., Bolis, G., Castelli, C., and Parmiani, G. Generation and phenotypic characterization of new human ovarian cancer cell lines with the identification of antigens potentially recognizable by HLA-restricted cytotoxic T cells. Int. J. Cancer, 73: 143-150, 1997.
35. Ottensmeier, C., Swanson, L., Strobel, T., Druker, B., Niloff, J., and Cannistra, S. A. Absence of constitutive EGF receptor activation in ovarian cancer cell lines. Br. J. Cancer, 74: 446-452, 1996.
36. Teicher, B. A., Holden, S. A., Ara, G., and Chen, G. Transforming growth factor-β in in vivo resistance. Cancer Chemother. Pharmacol., 37: 601-609, 1996.
37. Wojtowicz-Praga, S. Reversal of tumor-induced immunosuppression: a new approach to cancer therapy [see comments]. J. Immunother., 20: 165-177, 1997.